Forte Biosciences, Inc. has entered into a definitive merger agreement with argenx BV, a Belgian biopharmaceutical company, under which argenx will acquire Forte for $77.00 per share in an all-cash transaction announced on July 26, 2026. The transaction is structured as a two-step process consisting of a tender offer followed by a merger, with Forte's board of directors unanimously recommending that stockholders accept the offer. The acquisition represents a significant strategic move in the biopharmaceutical sector and is expected to proceed subject to customary closing conditions and regulatory approvals.

Key Points

  • NASDAQ: FBRX
  • Forte Biosciences agreed to be acquired by argenx BV for $77.00 per share in an all-cash transaction
  • The tender offer is expected to commence within 10 business days of the July 26, 2026 agreement date and will remain open for a minimum of 15 business days
  • Forte's board of directors unanimously recommended that stockholders accept the offer and tender their shares
  • Consummation of the tender offer is not subject to a financing condition

Transaction Structure and Merger Framework

The acquisition of Forte Biosciences by argenx BV is structured as a two-step transaction designed to efficiently transfer ownership and integrate the companies. The process begins with a tender offer in which argenx's wholly owned subsidiary, Avena Merger Sub Inc., will offer to acquire all issued and outstanding shares of Forte common stock for $77.00 per share, net to the seller in cash without interest. Following successful completion of the tender offer, argenx will effectuate a subsequent merger in which Avena Merger Sub will merge with and into Forte, with Forte continuing as the surviving corporation and becoming a wholly owned subsidiary of argenx.

The Merger Agreement specifies that the tender offer will be commenced within 10 business days of the July 26, 2026 execution date and will initially remain open for a minimum of 15 business days from the date of commencement, subject to extension in accordance with the agreement's terms. The use of this two-step structure allows argenx to acquire Forte efficiently while providing stockholders with an opportunity to tender their shares at the specified price. The subsequent merger under Section 251(h) of the Delaware General Corporation Law will proceed without requiring a separate stockholder vote, streamlining the integration process once the tender offer conditions are satisfied.

Offer Price and Stockholder Recommendation

The tender offer price of $77.00 per share represents the consideration that argenx is offering for each outstanding share of Forte common stock. This price is payable in cash, net to the seller, without interest, and is subject to any required withholding taxes. The Merger Agreement allows for potential amendment or adjustment of this price in accordance with the agreement's terms, though no such adjustments have been disclosed at this time. The all-cash nature of the transaction provides certainty regarding the consideration stockholders will receive upon completion of the tender offer.

Forte's board of directors has unanimously recommended that the company's stockholders accept the tender offer and tender their shares to argenx's subsidiary, Purchaser. This unanimous recommendation carries significant weight for stockholders evaluating the transaction, as it reflects the board's assessment that the offer is fair and in the best interests of the company and its shareholders. The board's support for the transaction and its recommendation that shareholders participate in the tender offer are key developments for investors considering their options regarding the acquisition.

Closing Conditions and Regulatory Requirements

The completion of the tender offer is subject to satisfaction or waiver of several conditions outlined in the Merger Agreement. A critical condition is the Minimum Condition, which requires that validly tendered and not validly withdrawn shares, when considered together with any shares beneficially owned by argenx and its affiliates, must represent more than 50% of the total number of Forte shares outstanding immediately following the tender offer's consummation. Additionally, the obligation of argenx and Purchaser to complete the offer is conditioned upon accuracy of Forte's representations and warranties contained in the agreement, subject to certain materiality exceptions, and material compliance by Forte with its covenants under the Merger Agreement.

The agreement specifies that consummation of the tender offer is not subject to a financing condition, meaning argenx is not relying on obtaining financing to complete the acquisition. Other customary closing conditions include expiration or early termination of the waiting period applicable under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended. The disclosure that the transaction is not financing-conditioned provides additional certainty regarding completion, as this eliminates one significant category of risk that could otherwise delay or prevent the transaction from closing.

Treatment of Company Equity Awards and Options

The Merger Agreement contains detailed provisions regarding the treatment of various equity instruments held by Forte employees and other security holders. Company options to purchase shares that are outstanding and unexercised at the effective time of the merger will receive treatment based on whether the option's per-share exercise price is less than the Merger Consideration. Options with exercise prices below the $77.00 Merger Consideration will be canceled and converted into a lump-sum cash payment equal to the excess of the Merger Consideration over the exercise price, multiplied by the total number of shares subject to the option.

Company options with per-share exercise prices equal to or greater than the Merger Consideration will be canceled without any consideration paid to the holder. Additionally, each Company restricted stock unit outstanding at the effective time of the merger, regardless of vesting status, will be canceled and converted into a right to receive a lump-sum cash payment equal to the Merger Consideration multiplied by the total number of shares subject to the restricted stock unit. All cash payments to option and restricted stock unit holders are subject to applicable withholding taxes. Company pre-funded warrants outstanding at the time of offer acceptance will become exercisable for the right to receive the Merger Consideration in respect of each share issuable upon full exercise, without regard to limitations on exercise contained in the warrant agreement.

Merger Consideration and Share Treatment at Closing

At the effective time of the merger, each issued and outstanding share of Forte common stock will be converted into the right to receive $77.00 in cash, subject to certain exceptions. Shares owned by Forte, argenx, Purchaser, or wholly owned direct or indirect subsidiaries of either company will not receive merger consideration. Additionally, shares that are irrevocably accepted for purchase pursuant to the tender offer will not be converted into the right to receive merger consideration, as those shares will have already been purchased during the tender offer phase at the offer price. Shares for which holders have properly exercised and perfected their respective demands for appraisal rights under Section 262 of the Delaware General Corporation Law are also excepted from this conversion.

The merger consideration is payable in cash without interest and is subject to any required withholding taxes. The specification of these exceptions is important for understanding which shares will ultimately receive the $77.00 per share consideration and how the transaction will affect different categories of shareholders. Shareholders who participate in the tender offer will receive their consideration through that process, while those who do not tender during the offer phase will receive their consideration through the subsequent merger, provided they do not exercise appraisal rights.

Covenants and Ordinary Course of Business Restrictions

Under the terms of the Merger Agreement, Forte has agreed to operate its business in the ordinary course, consistent with past practices, from the date of the agreement until the earlier of the effective time of the merger or termination of the agreement. The company is restricted from taking certain actions during this interim period, with the full scope of these restrictions set forth in the Merger Agreement itself. These ordinary course covenants are designed to ensure that Forte maintains its business operations and financial condition without undergoing material changes that could affect the value of the acquisition or the company's ability to consummate the transaction.

Both argenx and Purchaser have agreed to use reasonable best efforts to take all actions necessary to consummate the tender offer, the merger, and other transactions contemplated by the agreement. This commitment to reasonable best efforts extends to obtaining any necessary approvals, satisfying conditions, and addressing any regulatory or legal requirements that may arise during the interim period between signing and closing. The inclusion of reasonable best efforts language reflects the parties' commitment to completing the transaction and provides some assurance to Forte's shareholders that the acquirer will actively work toward consummation.

No-Shop Restrictions and Superior Offer Procedures

Forte has agreed to customary no-shop restrictions that limit its ability to solicit alternative acquisition proposals from third parties and restrict engagement in discussions or negotiations regarding such proposals. However, the Merger Agreement recognizes fiduciary obligations and provides that prior to the offer acceptance time, Forte may, under certain circumstances, provide information to and participate in discussions or negotiations with third parties regarding an alternative acquisition proposal that the board has determined constitutes or would reasonably be expected to result in a Superior Offer. The agreement defines a Superior Offer as a bona fide written acquisition proposal for a majority of the company that did not result from a material breach of the no-shop restrictions and that the board determines in good faith judgment, after consultation with outside legal counsel and its financial advisor, is reasonably likely to be consummated in accordance with its terms.

The Superior Offer definition includes consideration of legal, regulatory, and financing aspects of the proposal and the proposing party, among other factors. This framework allows the Forte board to continue fulfilling its fiduciary duties to shareholders while providing argenx with protection against the company pursuing alternative transactions. The ability to consider Superior Offers is a standard feature in merger agreements and reflects a balance between the acquirer's interest in certainty and the target company board's obligation to shareholders to evaluate other potential transaction opportunities that might provide greater value.

Representations, Warranties, and Customary Protections

The Merger Agreement contains representations and warranties customary for a transaction of this nature, representing the typical protections each party provides regarding the accuracy of statements and the validity of claims made in connection with the acquisition. These representations and warranties cover standard aspects of corporate transactions and provide each party with recourse should the other party's representations prove inaccurate. The agreement specifies that the accuracy of Forte's representations and warranties is a closing condition, subject to certain materiality exceptions, ensuring that the acquiring party has protections regarding the company's financial condition, legal compliance, and other material matters.

The customary nature of these protections reflects standard market practice in acquisitions of this type. Both parties' representations and warranties provide the contractual framework for the parties' mutual obligations and the bases upon which either party could potentially refuse to complete the transaction if representations prove materially inaccurate. The inclusion of materiality exceptions in the closing conditions is a typical feature that prevents minor or immaterial inaccuracies from providing grounds for deal termination.

Timeline and Next Steps for Shareholders

The tender offer is expected to commence within 10 business days of the Merger Agreement's July 26, 2026 execution date and will remain open for a minimum of 15 business days from commencement. Shareholders who wish to participate in the tender offer will need to tender their shares within this timeframe, subject to the possibility of extension if certain conditions are met. Following the offer acceptance time, when Purchaser has determined that sufficient shares have been validly tendered to satisfy the Minimum Condition and other closing requirements, the subsequent merger will be effected under Delaware law.

The timeline contemplates that the subsequent merger will proceed as soon as practicable following the offer acceptance time, subject to satisfaction or waiver of limited customary conditions. Shareholders should monitor communications from Forte and the tender offer documents that will be filed with the Securities and Exchange Commission for specific dates, procedures for tendering shares, and additional details regarding the transaction. Investors may wish to consult with financial and tax advisors regarding the implications of the transaction for their individual circumstances, including tax consequences and the timing of consideration receipt.

Immediate Share Price Impact and Market Implications

The immediate share price impact was not clear from available public information at the time of the announcement. However, the offer price of $77.00 per share represents the consideration at which argenx values Forte's shares and the amount that shareholders will receive upon successful completion of the transaction. The all-cash nature of the offer and the board's unanimous recommendation to accept it are factors that may influence how the market responds to the announcement and the stock's trading activity in coming days.

Investors should note that trading in Forte's common stock will likely continue during the interim period between announcement and closing of the transaction. The stock may trade at or near the $77.00 offer price, though it could also trade at a discount if market participants perceive risk that the transaction may not be completed. Factors that could affect trading include progress toward satisfying closing conditions, regulatory developments, and any statements by either party regarding the transaction's status. Shareholders who do not tender during the offer phase but hold their shares until the effective time of the merger will receive the $77.00 per share consideration through the merger process.